NYSE: PTN - Palatin Technologies, Inc.

Rentabilität für sechs Monate: -79.47%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Palatin Technologies, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Palatin Technologies, Inc.

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases.

weitere details
In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 1993-10-28
ISIN US6960775020
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://palatin.com
Цена ао 0.7218
Preisänderung pro Tag: 0% (0.2053)
Preisänderung pro Woche: -53.55% (0.442)
Preisänderung pro Monat: -74.66% (0.8101)
Preisänderung über 3 Monate: -80.99% (1.08)
Preisänderung über sechs Monate: -79.47% (1)
Preisänderung pro Jahr: -89.19% (1.9)
Preisänderung über 3 Jahre: -54.38% (0.45)
Preisänderung über 5 Jahre: -48.68% (0.4)
Preisänderung seit Jahresbeginn: -79.26% (0.99)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 5.96 2
P/BV -239.91 0
P/E 0 0
EV/EBITDA -0.6135 0
Gesamt: 4

Effizienz

Name Bedeutung Grad
ROA, % -207.35 0
ROE, % -263431.19 0
Gesamt: 1.67

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0.0071

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0203 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 3705.16 10
Rentabilität Ebitda, % 23.01 4
Rentabilität EPS, % -10.08 0
Gesamt: 4
Weitere Details

Institutionen Volumen Aktie, %
Armistice Capital, LLC 590000 3.66
Vanguard Group Inc 548622 3.4
LPL Financial LLC 146396 0.91
Blackrock Inc. 119518 0.74
Geode Capital Management, LLC 94148 0.58
State Street Corporation 30295 0.19
Susquehanna International Group, LLP 30062 0.19
Bridgeway Capital Management, Inc. 26124 0.16
Northern Trust Corporation 25097 0.16
Montis Financial, LLC 20964 0.13



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Carl Spana Ph.D. Co-Founder, President, CEO & Director 979k 1962 (63 Jahr)
Mr. Stephen T. Wills CPA, MST CFO, COO, Executive VP, Treasurer & Secretary 910.55k 1957 (68 Jahre)
Burns McClellan Vice President of Investor Relations N/A
Mr. Stephen A. Slusher Esq. Chief Legal Officer N/A
Dr. Michael B. Raizman M.D. Chief Medical Officer N/A
Mr. James E. Hattersley Senior Vice President of Business Development N/A 1960 (65 Jahre)
Mr. John Dodd Ph.D. Senior Vice President of Preclinical Development N/A
Mr. Robert Jordan Senior Vice President of Program Operations N/A

Adresse: United States, Cranbury. NJ, Cedar Brook Corporate Center - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://palatin.com